We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Animal Model and Predictive Test Developed for Preeclampsia

By LabMedica International staff writers
Posted on 28 Oct 2010
Scientists have developed a well-defined animal model of preeclampsia and a potential lab test for diagnosing the disease in people. More...
Preeclampsia is a potentially dangerous condition that sometimes occurs during pregnancy and can be fatal for both mother and fetus.

The presence of the immune system secretion Interleukin-10 (IL-10) has been linked to a successful course of pregnancy. Scientists from Brown University and Women & Infants Hospital experimented with mice genetically engineered to lack IL-10. They isolated blood serum from human patients with preeclampsia, gave a dose of it to the mice, and the rodents developed preeclampsia symptoms. Further experiments with nonpregnant mice and pregnant wild mice confirmed that pregnant mice lacking IL-10 provide a unique and dependable model of the disease.

An animal model for preeclampsia will allow for experiments that help gain insight into the cause of the disease and its progression said Surendra Sharma, professor of pediatrics at the Warren Alpert Medical School of Brown University (Providence, RI, USA) and a research scientist at Women & Infants. One observation already made is that there is disruption in the development of "spiral arteries,” which bring nutrients to the fetus from the placenta.

This observation led to the development of a predictive test for preeclampsia. An in vitro culture of two key cell types involved in spiral artery development (endothelial cells and trophoblasts) was exposed to serum from women with normal pregnancies or to preeclampsia serum from women taken at various stages of their pregnancies.

Vasculature developed normally in the presence of serum from women with normal pregnancies whereas preeclampsia serum taken from women as early as 12 to 14 weeks into their pregnancies, about 10 to 12 weeks before they were diagnosed with preeclampsia, was able to disrupt vascular formation.

Prof. Sharma is continuing to refine the test for eventual clinical use.

Related Links:

Warren Alpert Medical School of Brown University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.